Anlotinib also acts on tumor progression and cell proliferation by inhibiting PDGFR alfa/beta, c-Kit, Ret, Aurora-B, c-FMS, and discoidin domain receptor 1 and carrying mutations in PDGFR alfa, c-Kit, Met, and EGFR. This evidence concerns the gene KIT and neoplasm.